Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T71029 |
RCC-36 HCl
|
||
Rcc 36 is an active metabolite of temiverine that has inhibitory actions toward the atropine-resistant part of contractions, which may be related to the calcium antagonistic actions of these compounds. | |||
T26046 |
Razoxane
|
Topoisomerase | DNA Damage/DNA Repair |
Razoxane 是拓扑异构酶 II 的有效抑制剂,具有抗血管生成的作用,在肾细胞癌中具有研究价值。 | |||
T6683 |
STF-62247
STF 62247 |
Estrogen/progestogen Receptor; Autophagy | Autophagy; Endocrinology/Hormones |
STF-62247 是一种自噬诱导剂,在 RCC4 和 RCC4/VHL 细胞中的IC50分别为 0.625 μM 和 16 μM。它对 VHL 缺陷型肾细胞癌有选择性的细胞毒性。 | |||
T71027 | KDI-792 hydrochloride | ||
KDI-792 hydrochloride is a thromboxane dual blocker. | |||
T9698 |
UC2288
|
Mdm2; p53 | Apoptosis |
UC2288 是新型的、细胞通透性、口服有效的p21衰减试剂,基于索拉非尼的结构合成。在不依赖 于p53的情况下,它可以下调 p21 mRNA 的表达,降低 p21 蛋白水平,对 p21 蛋白的稳定性影响很小。它对VEGFR2 和 Raf 激酶没有抑制作用,即使在 10 μM。 | |||
T60904 |
ERCC1-XPF-IN-2
|
Others | Others |
ERCC1-XPF-IN-2 在核苷酸切除修复、顺铂增强和 γH2AX 测定中具有活性。ERCC1-XPF-IN-2 是 ERCC1-XPF 核酸内切酶的有效抑制剂,IC50值为 0.6 μM。 | |||
T41227 |
ARCC 4 negative control
|
||
ARCC 4 negative control is a negative control for ARCC 4. Binds androgen receptors (AR) without inducing degradation. | |||
T14318 |
ARCC-4
|
Others | Others |
ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide and it is a low-nanomolar androgen receptor (AR) degrader based on PROTAC, with a DC50 of 5 nM. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy[1]. | |||
T63464 | ERCC1-XPF-IN-1 | ||
ERCC1-XPF-IN-1 是有效的、高亲和力的 ERCC1-XPF 抑制剂 (IC50: 0.49 μM)。ERCC1-XPF-IN-1 能够抑制 CPDs 的去除,降低环磷酰胺对结直肠癌细胞的毒性,提高了 UV 辐射的细胞毒性作用,阻碍 DNA 修复。 | |||
T63505 |
Tivozanib hydrochloride hydrate
|
||
Tivozanib hydrochloride hydrate 是选择性的、有效的、口服具有活力的 VEGFR 酪氨酸激酶抑制剂,能够作用于 VEGFR-1 (IC50: 0.21 nM)、VEGFR-2 (IC50: 0.16 nM)、VEGFR-3 (IC50: 0.24 nM)。Tivozanib hydrochloride hydrate 能够抑制肿瘤组织中的血管生成和血管通透性,并具有抗肿瘤作用,对转移性肾细胞癌 (RCC) 具有研究潜力。 | |||
T76723 | Tilvestamab | ||
Tilvestamab (BGB149) 是一种人源化抗AXL 抗体,阻断AXL 介导的细胞信号传导。Tilvestamab 在体外能显著抑制Gas6刺激诱导的AXL 激活,并抑制 786-0-Luc RCC 细胞中下游AXL 的磷酸化。Tilvestamab 可用于癌症,尤其是AXL 过度表达肾细胞癌的研究。 |